Previous 10 | Next 10 |
Halberd ( OTCPK:HALB ) has announced the formation of Halberd Cancer Therapeutics, as a wholly owned subsidiary. Halberd's patented extracorporeal technology has demonstrated the capacity for successful application to a wide variety of diseases and health-related illnesses. ...
JACKSON CENTER, PA / ACCESSWIRE / July 20, 2022 / Halberd Corporation (OTC PINK:HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary. Halberd's patented extracorporeal technology has demonstrated the capacity for successful application to a wide v...
Boosts Effectiveness of Commercial Covid Antibodies by 45% Jackson Center, Pennsylvania--(Newsfile Corp. - July 14, 2022) - Halberd Corporation (OTC Pink: HALB) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in ...
Boosts Effectiveness of Commercial Covid Antibodies by 45% JACKSON CENTER, PA / ACCESSWIRE / July 14, 2022 / Halberd Corporation (OTC PINK:HALB) researchers developed, with appropriate protocols, a SARS-CoV-2 antibody effective against all four Covid-19 mutations currently in circulat...
Q2 Accomplishments and a Look to the Future Jackson Center, Pennsylvania--(Newsfile Corp. - July 12, 2022) - Halberd Corporation (OTC Pink: HALB) This past quarter has witnessed some very significant technical and organizational achievements by the Halberd team. The accomplishments for the ...
Halberd Corporation (OTC PINK: HALB), after recognizing the depth of application of its recently patented extracorporeal treatment approach, has announced the creation of a new subsidiary. The subsidiary comprises a group of researchers focusing on cancer treatment. The techno...
Halberd Corp (OTCPK:HALB) said on Tuesday it had created a subgroup of researchers to focus on cancer treatment and expects the new cancer subgroup to eventually be spun off as a separate company. The company said the subgroup will be guided by its existing technical team members. T...
JACKSON CENTER, PA / ACCESSWIRE / June 21, 2022 / Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC PINK:HALB) announced the creation of a subgroup of researchers to focus on cancer treatment. Halberd's technology is capable ...
Jackson Center, Pennsylvania--(Newsfile Corp. - June 8, 2022) - Halberd Corporation (OTC Pink: HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd's patented extracorporeal ...
JACKSON CENTER, PA / ACCESSWIRE / June 8, 2022 / Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) executed a non-disclosure agreement (NDA) to explore animal testing as the next step in obtaining FDA certification for Halberd's patented extracorporeal disease erad...
News, Short Squeeze, Breakout and More Instantly...
Walt Disney once said, "All our dreams can come true if we have the courage to pursue them". JACKSON CENTER, PA / ACCESSWIRE / May 22, 2024 / Halberd Corporation (OTC PINK:HALB) in cooperation with Athena GTX, Inc is standing at the threshold of some major advancements to treat the issues ...
Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously. JACKSON CENTER, PA / ACCESSWIRE / May 9, 2024 / Halberd Corporation's (OTC PINK:HALB) two active programs for the treatment and mitigation of the negative ...
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to...